New data demonstrates SOF-16, the active ingredient in SOF-SKN, effectively blocks inflammation in blood and joint fluid samples from lupus and rheumatoid arthritis patients. This supports further development of SOF-SKN for autoimmune diseases. Announcement: www.noxopharm.com/pdf/e6d6d6bf...
